Open Access

Transcatheter options for the management of HF patients with MR or TR: the new ESC-HF and ESC/EACTS VHD guidelines

Event: ESC Congress 2021 - The Digital Experience
Topic: Chronic Heart Failure
Session type: Satellite Symposium
Sponsored by Edwards Lifesciences
Date: 29 August 2021
Time: 09:00 - 09:30

Session

This content is currently on OPEN ACCESS

Sign in to view the resources

5 presentations in this session

Session opening​.

Speaker: Professor J. Bax (Leiden, NL)
Thumbnail

Supporting HF treatment through transcatheter valve therapy​.

Speaker: Professor M. Boehm (Homburg, DE)
Thumbnail

ESC-HF guidelines for management of MR and TR: the update and its clinical implications.

Speaker: Professor J. Bax (Leiden, NL)
Speaker: Professor R. Von Bardeleben (Mainz, DE)
Speaker: Professor M. Boehm (Homburg, DE)
Thumbnail

Successful treatment of MR and TR patients​ with differentiated transcatheter technologies.

Speaker: Professor R. Von Bardeleben (Mainz, DE)
Thumbnail

Session evaluation and key learnings​.

Speaker: Professor J. Bax (Leiden, NL)
Thumbnail

7 speakers from this session

Professor Jeroen Bax

Leiden University Medical Centre, Leiden (Netherlands (The))
59 presentations
1 follower

Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)
56 presentations
0 follower

Professor Jeroen Bax

Leiden University Medical Centre, Leiden (Netherlands (The))
59 presentations
1 follower

Professor Ralph Stephan Von Bardeleben

University Medical Center of Mainz, Mainz (Germany)
51 presentations
1 follower

Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)
56 presentations
0 follower

Professor Ralph Stephan Von Bardeleben

University Medical Center of Mainz, Mainz (Germany)
51 presentations
1 follower

Professor Jeroen Bax

Leiden University Medical Centre, Leiden (Netherlands (The))
59 presentations
1 follower

Related content

ESC Premium Access

Update on endocarditis in 2021

3 December 2021

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

ESC Premium Access

Current controversies in antithrombotic therapy

3 December 2021

This platform is supported by

logo Novo Nordisk